



265 Watline Avenue, Mississauga, Ontario L4Z 1P3
Tel: 905-361-8910 Fax: 905-361-8911

News Release

Microbix Announces Annual and Special Meeting Voting Results

TORONTO April 7, 2016 — Microbix Biosystems Inc. (TSX: MBX) (“Microbix” or the “Company”), an innovator of biological products and technologies, announces the results of the Annual and Special Meeting of Shareholders that was held on April 6, 2016, at which 45.98% of the issued and outstanding shares were represented. Shareholders voted in favour of all resolutions brought before the meeting. A detailed description of all resolutions that were voted on can be reviewed in the Company’s Information Circular, which was filed on SEDAR on March 7, 2016. All of the director nominees listed in the Information Circular were re-elected as directors of Microbix. Detailed results of the vote are set out below:

Nominee	For	% For	Withheld	% Withheld
Peter M. Blecher	33,185,048	92.15	2,827,666	7.85
Mark A. Cochran	32,116,298	89.18	3,896,416	10.82
Vaughn C. Embro-Pantalony	34,399,245	95.52	1,613,469	4.48
William J. Gastle	32,360,265	89.86	3,652,449	10.14
Andrew C. Pollock	31,556,494	87.63	4,456,220	12.37
Joseph D. Renner	34,615,814	96.12	1,396,900	3.88
Martin Marino	30,705,244	85.26	5,307,470	14.74
Cameron Groome	31,557,744	87.63	4,454,970	12.37

In addition, shareholders approved resolutions: appointing the Company’s auditors, Collins Barrow Toronto LLP with 91.81% of the votes cast in favour; and the Company’s advance notice bylaw in respect of election of directors with 92.25% of the votes cast in favour.

About Microbix Biosystems

Microbix Biosystems Inc. specializes in the research and development of biological solutions. This includes products for human health applications in the vaccine, therapeutic and diagnostic markets and a product for the worldwide animal reproduction market. In its revenue generating business, the Company manufactures and distributes a wide range of infectious disease antigens

to a worldwide customer base. The Company's pipeline of innovative technologies and products includes LumiSort™ semen sexing technology for the livestock industries, Kinlytic®, a thrombolytic drug with several approved and potential applications including the treatment of life-threatening blood clots, and VIRUSMAX®, a proprietary technology for increasing virus yields in the manufacture of influenza vaccine. Established in 1988, Microbix is a publicly traded company, listed on the Toronto Stock Exchange, and headquartered in Mississauga, Ontario.

Forward-Looking Information

This news release includes "forward-looking information," as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, the risks associated with its revenue business, development projects, operations in foreign jurisdictions, engineering and construction generally, production (including control over costs, quality, quantity and timeliness of delivery of products), foreign currency and exchange rates, maintaining adequate working capital and raising further capital on acceptable terms or at all, and other similar statements concerning anticipated future events, conditions or results that are not historical facts. These statements reflect management's current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward looking information is inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent the Company's judgement as of the date of this new release, and the Company is under no obligation to update or alter any forward-looking information.

Please visit www.sedar.com for recent Microbix Biosystems Inc. filings.

For further information, please visit www.microbix.com or contact:

Company Contacts:

Vaughn C. Embro-Pantalony, CEO
(905) 361-8910 x 350
vaughn.embro-pantalony@microbix.com

Charles Wallace, CFO
(905) 361-8910 x 255
charles.wallace@microbix.com

Stephen Kilmer, Investor Relations
(647) 872-4849
stephen.kilmer@microbix.com